Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
- PMID: 32854103
- DOI: 10.1159/000510703
Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
Abstract
Introduction: Esketamine nasal spray received approval for treatment-resistant depression in March 2019.
Objective: Using the FDA Adverse Event Reporting System (FAERS) database (March 2019-March 2020), we analysed esketamine-related adverse events (AEs) to detect and characterize relevant safety signals.
Methods: We used the consolidated case/non-case approach to estimate the reporting odds ratio (ROR) and information component (IC) with relevant confidence intervals (95% CI) for esketamine-related AEs with ≥4 counts. Comparisons between serious and non-serious AEs were performed using non-parametric tests.
Results: The FAERS database contained 962 cases of esketamine-related AEs, with signals detected for several AEs, such as dissociation (ROR = 1,612.64, 95% CI = 1,354.63, 1,919.79; IC = 8.19, 95% CI = 7.96, 8.35), sedation (ROR = 238.46, 95% CI = 202.98, 280.15; IC = 7, 95% CI = 6.75, 7.18), feeling drunk (ROR = 96.17, 95% CI = 61.42, 150.57; IC = 4.84, 95% CI = 4.09, 5.36), suicidal ideation (ROR = 24.03, 95% CI = 18.72, 30.84; IC = 4.31, 95% CI = 3.9, 4.61), and completed suicide (ROR = 5.75, 95% CI = 3.18, 10.41; IC = 2.25, 95% CI = 1.23, 2.94). Signals for suicidal and self-injurious ideation, but not suicide attempt and completed suicide, remained when comparing esketamine to venlafaxine. Females and patients receiving antidepressant polypharmacy, co-medication with mood stabilizers, antipsychotics, benzodiazepines, or somatic medications were more likely to suffer from serious versus non-serious AEs (χ2 = 125.29, p < 0.001, χ2 = 9.08, p = 0.003, χ2 = 8.14, p = 0.004, χ2 = 19.48, p < 0.001, χ2 = 25.62, p < 0.001, and χ2 = 16.79, p < 0.001, respectively).
Conclusions: Esketamine may carry a clear potential for serious AEs, which deserves urgent clarification by means of further prospective studies.
Keywords: Adverse drug reactions; Esketamine; Pharmacovigilance; Suicidality; Treatment-resistant depression.
© 2020 S. Karger AG, Basel.
Comment in
-
Reply to the Comments by Doherty et al.Psychother Psychosom. 2021;90(2):140-141. doi: 10.1159/000511830. Epub 2020 Oct 22. Psychother Psychosom. 2021. PMID: 33091915 No abstract available.
-
Comments to Drs. Gastaldon, Raschi, Kane, Barbui, and Schoretsanitis.Psychother Psychosom. 2021;90(2):138-139. doi: 10.1159/000512311. Epub 2020 Oct 27. Psychother Psychosom. 2021. PMID: 33108791 Free PMC article. No abstract available.
Similar articles
-
Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System.Front Pharmacol. 2022 Apr 8;13:849758. doi: 10.3389/fphar.2022.849758. eCollection 2022. Front Pharmacol. 2022. PMID: 35462924 Free PMC article.
-
Post-marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.Br J Clin Pharmacol. 2023 Sep;89(9):2830-2842. doi: 10.1111/bcp.15783. Epub 2023 May 25. Br J Clin Pharmacol. 2023. PMID: 37170890
-
The association between ketamine and esketamine and suicidality: reports to the Food And Drug Administration Adverse Event Reporting System (FAERS).Expert Opin Drug Saf. 2024 Jun 21:1-6. doi: 10.1080/14740338.2024.2368827. Online ahead of print. Expert Opin Drug Saf. 2024. PMID: 38884147
-
SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports.Int J Clin Pharm. 2022 Dec;44(6):1425-1433. doi: 10.1007/s11096-022-01476-7. Epub 2022 Oct 12. Int J Clin Pharm. 2022. PMID: 36224513 Review.
-
Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.Drug Saf. 2018 Apr;41(4):357-361. doi: 10.1007/s40264-017-0622-2. Drug Saf. 2018. PMID: 29196988 Review.
Cited by
-
Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database.Front Pharmacol. 2024 May 9;15:1389814. doi: 10.3389/fphar.2024.1389814. eCollection 2024. Front Pharmacol. 2024. PMID: 38783948 Free PMC article.
-
Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system.BMC Infect Dis. 2024 May 9;24(1):446. doi: 10.1186/s12879-024-09339-4. BMC Infect Dis. 2024. PMID: 38724914 Free PMC article.
-
New Adverse Drug Reaction Signals from 2017 to 2021-Genuine Alerts or False Alarms?Pharmacy (Basel). 2024 Feb 10;12(1):33. doi: 10.3390/pharmacy12010033. Pharmacy (Basel). 2024. PMID: 38392940 Free PMC article. Review.
-
The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database.Eur Arch Psychiatry Clin Neurosci. 2023 Dec 16. doi: 10.1007/s00406-023-01732-5. Online ahead of print. Eur Arch Psychiatry Clin Neurosci. 2023. PMID: 38103077
-
Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system.Int J Clin Pharm. 2024 Jun;46(3):614-622. doi: 10.1007/s11096-023-01673-y. Epub 2023 Dec 15. Int J Clin Pharm. 2024. PMID: 38100054
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical